Opendata, web and dolomites

ASPIVIX

Vacuum Medical Device for Safe and Gentle Cervix Grasping Gynecological Applications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ASPIVIX project word cloud

Explore the words cloud of the ASPIVIX project. It provides you a very rough idea of what is the project "ASPIVIX" about.

contraceptive    insertions    adoption    tenaculum    gynecological    euros    forceps    bleeding    iucd    revenues    aspivix    roi    exacerbates    pregnancies    painful    patented    firm    yearly    traumatic    350m    pain    curettage    unintended    besides    patients    shorten    female    thanks    2021    refrain    for    replace    women    care    intended    risk    physician    markets    benefit       eradicates    84    inside    22m    procedure    units    social    vaginal    gentle    north    gynecologists    market    grow    grasping    sales    return    pulling    traction    64       prevents    disruptive    valued    uterine    cagr2016    invested    economic    uterus    lesions    exploration    cumulative    trigger    cervix    reduces    29    cavity    considering       representing    asian    instead    generate    sized    billions    85    investment    disadvantages    10    28    single    demand    reduce    device    cross    proved    total    fulfill    contamination    practices    featured    poor    worldwide    nearly    intervention    infection    indications    american    gynecologist    6m    projected    unchanged    mills   

Project "ASPIVIX" data sheet

The following table provides information about the project.

Coordinator
ASPIVIX SA 

Organization address
address: CHEMIN DE RENENS 2 BIS
city: LAUSANNE
postcode: 1004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.aspivix.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASPIVIX SA CH (LAUSANNE) coordinator 50˙000.00

Map

 Project objective

For years, gynecologist practices related to Intra-Uterine Contraceptive Device (IUCD) insertions, curettage and several other common indications, have featured poor care and low attention to female patients.
The use of the Tenaculum, grasping and pulling on the cervix, inside the vaginal cavity, proved to be painful and traumatic for 84% of the women, and eventually to trigger lesions and bleeding in 29% of the patients, as well as cross-contamination in 5-10% of the women. These disadvantages refrain the use of IUCD contraceptive which exacerbates the unintended pregnancies, sized yearly in 85 mills and representing billions of euros in social costs worldwide. In response, we have developed Aspivix, a new disruptive gynecological device that reduces the pain and eradicates the bleeding during the exploration procedure. Our patented device will replace the Tenaculum forceps, unchanged for over 100 years, to provide gynecologists an easy-to-use device where gentle and firm cervix uterus grasping and traction is needed. Thus, our device will facilitate the adoption of IUCD, which could avoid up to 8% of unintended pregnancies and reduce derived social costs. Besides, Aspivix is intended for a single use which prevents the risk of contamination and cross-infection. Overall, Aspivix has the potential to shorten the intervention procedure (2 steps instead 7), which will represent for the physician a 28% economic benefit. As result, Aspivix will fulfill the needs of more than 64 M of women worldwide/year, a market that is projected to grow at a CAGR2016-2021 of ~6.5% due to the high demand of IUCD insertions and is valued in more than €350M. In this way, thanks to the sales of 22M units in the European, Asian and North American Markets after 5-years, Aspivix will generate cumulative revenues of nearly €80 M and, considering the total investment of €3.6M, a return of investment (ROI) of €8.3 per euro invested.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ASPIVIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ASPIVIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Path Feel (2019)

Insoles for Neuropathy and Balance Issues

Read More